Obese PatientsNCT06771986
Soluble Advanced Glycation End Product (sRAGE) Levels
An observational study of Obese Patients, run by Kayseri City Hospital at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study is to evaluate sRAGE levels in children with obesity and to determine the relationship between metabolic status and sRAGE levels in childhood obesity Read more about this study
- Who is it for?
- Ages 10 to 18 years
- Conditions the study is for
- Obese Patients
- What is being tested?
- Observation
- How many people
- 88 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 2 Feb 2023to 1 Jan 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Obese and Healthy children who admitted to Kayseri City Hospital
Who may be able to join
- Clinical diagnosis of Obesity BMI over 95th percentile BMI z-score over 2
Who cannot join
- Primary hyperlipidemia Primary liver disease Hypothyroidism Diabetes
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Soluble Advanced Glycation End Product (sRAGE) Levels in Childhood Obesity
The aim of this study is to evaluate sRAGE levels in children with obesity and to determine the relationship between metabolic status and sRAGE levels in childhood obesity
- Conditions
- Obese Patients
- Being tested
- Observation
- Keywords
- Children, obesity, sRAGE
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ObservationOther
sRAGE levels were studied in three different groups
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of sRAGE levels in obese and healthy participants
Measured: From enrollment to the end of at 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2025
- Study start2 Feb 2023
- Primary completion12 Aug 2023
- Study completion1 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Obese PatientsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 88 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kayseri City Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Pembe Soylu Ustkoyuncu, Kayseri City Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06771986
- Sponsor's protocol ID
- 791-2023
- Status last verified
- Jan 2025
- First submitted
- 3 Jan 2025
- Last updated
- 13 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- Individual data sharing
- No
Publications
Ustkoyuncu PS, Kocer D. Soluble receptor for advanced glycation end product (sRAGE) levels in adolescents with obesity, insulin resistance and metabolic syndrome: A case-control study and the review of the literature. BMC Endocr Disord. 2025 Sep 23;25(1):209. doi: 10.1186/s12902-025-02025-9.
PubMed 40983915
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Soluble Advanced Glycation End Product (sRAGE) Levels in Childhood Obesity
- ClinicalTrials.gov ID
- NCT06771986
- Acronym / sponsor ID
- 791-2023
- Conditions
- Obese Patients
- Keywords
- Children, obesity, sRAGE
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 88 participants (actual)
- Lead sponsor
- Kayseri City HospitalOther government
- Study start
- 2 Feb 2023 (actual)
- Primary completion
- 12 Aug 2023 (actual)
- Study completion
- 1 Jan 2024 (actual)
- First posted
- 13 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate sRAGE levels in children with obesity and to determine the relationship between metabolic status and sRAGE levels in childhood obesity
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Ages
- 10 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Obese and Healthy children who admitted to Kayseri City Hospital
Key inclusion criteria (1 listed)
- Clinical diagnosis of Obesity BMI over 95th percentile BMI z-score over 2
Key exclusion criteria (1 listed)
- Primary hyperlipidemia Primary liver disease Hypothyroidism Diabetes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ObservationsRAGE levels were studied in three different groups | Other | – |
Primary outcome
Evaluation of sRAGE levels in obese and healthy participants
Time frame: From enrollment to the end of at 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2025.
- Derived from this study: PubMed 40983915Ustkoyuncu PS, Kocer D. Soluble receptor for advanced glycation end product (sRAGE) levels in adolescents with obesity, insulin resistance and metabolic syndrome: A case-control study and the review of the literature. BMC Endocr Disord. 2025 Sep 23;25(1):209. doi: 10.1186/s12902-025-02025-9.
- Individual participant dataSharing planned: No
Related trials for Obese Patients
Not yet recruiting
OBEDIAM: Therapeutic Patient Education in Adults Living With Obesity, Diabetes, and Metabolic Disorders
Obesity (BMI>30)
Not yet recruiting
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Not yet recruiting
Evaluation of the Axomove Therapy Medical Device to Facilitate Adapted Physical Activity for Patients With Obesity
Obese Adults
Active, not recruiting
Mindfulness Based Eating Awareness Training for Bariatric Surgery Patients
Obesity, Morbid, Eating Disorder Symptom
Not yet recruitingPhase 2
Oxytocin for Respiratory Compromise and Hypoventilation Induced by Drugs
Obesity & Overweight, Respiratory Depression
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obese Patients, run by Kayseri City Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of sRAGE levels in obese and healthy participants (time frame: From enrollment to the end of at 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06771986, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2025.